Notice to Our Users - Redesigned National Guideline Clearinghouse (NGC) Coming Soon!We are redesigning the NGC Web site for release this summer! Responsive Web Design (RWD) techniques will provide a better viewing experience across a wide range of devices, from desktop and laptop computers, to tablets and mobile phones.
|In addition to the new design, NGC will feature updated searching capabilities by using filters and facets for refining your search results, and updated browsing capabilities for the Browse by Topic and Browse by Organization pages.|
The redesigned NGC Web site will be more intuitive, with an improved, new look and feel, but will maintain the same great content that has defined NGC for many years. For a preview, visit NGC.
SAVE THE DATE for the next Guidelines International Network North America (G-I-N/NA) Webinar
- Topic: New National Guideline Clearinghouse (NGC) and National Quality Measures Clearinghouse (NQMC) Web site Debuts
- Date: June 21, 2016, 4 PM EST/ 3 PM CST/ 1 PM PST
- Register in advance: https://cc.readytalk.com/
registration/#/?meeting= yx5dgg55xc71&campaign= zsdjh375fh8
- The Guidelines International Network (G-I-N) 13th annual conference will take place from September 27-30, 2016 in Philadelphia. This conference will be co-hosted by the American College of Physicians, ECRI Institute and Penn Medicine. The theme is "Individualised Guidelines and Clinical Performance Measurement in an Era of Personalised Medicine." Registration now open. For more information, visit the G-I-N Conference Web site.
U.S. Food and Drug Administration (FDA) Advisories
- May 10, 2016: Olanzapine: FDA is warning that the antipsychotic medicine olanzapine can cause a rare but serious skin reaction that can progress to affect other parts of the body. FDA is adding a new warning to the drug labels for all olanzapine-containing products that describes this severe condition known as Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS).
- May 12, 2016: Fluoroquinolone Antibacterial Drugs: FDA is advising that the serious side effects associated with fluoroquinolone antibacterial drugs generally outweigh the benefits for patients with sinusitis, bronchitis, and uncomplicated urinary tract infections who have other treatment options. For patients with these conditions, fluoroquinolones should be reserved for those who do not have alternative treatment options.
- May 18, 2016: Canagliflozin (Invokana, Invokamet): FDA is alerting the public about interim safety results from an ongoing clinical trial that found an increase in leg and foot amputations, mostly affecting the toes, in patients treated with the diabetes medicine canagliflozin (Invokana, Invokamet). FDA has not determined whether canagliflozin increases the risk of leg and foot amputations. FDA is currently investigating this new safety issue and will update the public when they have more information.
Health Awareness Topics - May 2016
- Arthritis Awareness Month (see related guidelines)
- Hepatitis Awareness Month (see related guidelines)
- Melanoma/Skin Cancer Detection and Prevention Month ® (see related guidelines)
- Mental Health Month (see related guidelines)
- National Asthma and Allergy Awareness Month (see related guidelines)
- National Osteoporosis Awareness and Prevention Month (see related guidelines and guideline synthesis)
- National Stroke Awareness Month (see related guidelines)
- Preeclampsia Awareness Month (see related guidelines)